GLP-1 drugs tied to lower heart risk in RA

A retrospective cohort study published in Clinical Rheumatology on 11 June 2026 found that non-diabetic adults with rheumatoid arthritis (RA) and obesity who received GLP-1-based therapy had roughly half the rate of heart failure or respiratory failure events compared with matched non-users^[1]. The study drew on the TriNetX US Collaborative Network, a federated database covering dozens of US healthcare organisations.

What the study measured

Researchers Giorgos Loizidis and Ross Summer identified non-diabetic adults diagnosed with RA who had a BMI of 30 or higher and who had started semaglutide or tirzepatide within 90 days of their index BMI measurement. All participants were on disease-modifying antirheumatic drugs, and anyone with diabetes or overlapping systemic autoimmune diseases was excluded. After propensity score matching across 68 covariates, each cohort contained 3,483 patients. The comparator group consisted of strict never-users of any GLP-1 agent^[1].

The primary outcome was the first ICD-10-documented heart failure or respiratory failure event between days 91 and 365 after the index date. A 90-day washout window excluded anyone who already had these diagnoses at baseline, helping isolate new events from pre-existing conditions^[1].

Key results

In the GLP-1 group, 23 of 3,176 patients (0.7%) experienced a primary event, compared with 57 of 3,144 (1.8%) in the never-user group. The adjusted hazard ratio was 0.48 (95% CI 0.30-0.78, p = 0.002), corresponding to a 52% relative reduction and a 1.1 percentage-point absolute risk difference^[1]. When heart failure and respiratory failure were analysed separately, both components showed "directionally similar associations," though individual significance was not reported.

Why RA patients face higher cardiopulmonary risk

RA drives systemic inflammation that accelerates atherosclerosis and myocardial dysfunction. A 2020 analysis in the Journal of the American Heart Association found that RA-related chronic inflammation independently raised the hazard of incident heart failure, even after adjusting for traditional cardiovascular risk factors^[2]. Add obesity to the picture, and the risk climbs further: obesity worsens RA disease activity, reduces the chance of treatment remission, and compounds the metabolic burden on the heart.

GLP-1 receptor agonists may address several of these pathways at once. Beyond weight reduction, they appear to exert anti-inflammatory effects and improve myocardial function. A 2025 JAMA analysis of real-world data from over 58,000 patients found that both semaglutide and tirzepatide substantially lowered the composite risk of heart failure hospitalisation or all-cause mortality in patients with heart failure with preserved ejection fraction (HFpEF), with hazard ratios of 0.58 and 0.42 respectively versus sitagliptin^[3].

Broader evidence in autoimmune disease

A separate large study published in the Journal of the American Heart Association in June 2026, analysing over 26,000 adults with obesity and various autoimmune diseases, reported that GLP-1 receptor agonist users had 44% lower all-cause mortality, 21% fewer emergency department visits, and 17% lower venous thromboembolism risk compared with non-users^[4]. That study used a target-trial emulation design on electronic health records from over 26 million patients in the OneFlorida+ network.

Taken together, these findings suggest that the benefits of GLP-1 therapies in autoimmune populations may extend beyond weight loss alone. Reduced systemic inflammation, improved vascular function, and lower metabolic stress on the heart could all contribute, though the relative importance of each mechanism remains unclear.

What the study does not tell us

The TriNetX analysis is retrospective and observational. Propensity score matching reduces but does not eliminate confounding. Patients prescribed GLP-1 agents may differ from non-users in ways that claims data cannot capture, such as health literacy, adherence to other treatments, or physical activity. The 90-day landmark design also means early events are excluded, which could bias results in either direction.

The study grouped semaglutide and tirzepatide together as "GLP-1-based therapy" and did not report results for each drug separately. Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 agonist, so its mechanism of action differs. Whether one agent outperforms the other in this population is unknown. The JAMA HFpEF analysis found no meaningful difference between the two for heart failure outcomes in a general population^[3], but RA-specific data do not exist.

Sample size matters too. Although 3,483 patients per arm is respectable for an RA subgroup analysis, only 80 primary events occurred in total. Rare outcomes measured over a short follow-up window can produce wide confidence intervals, and the lower bound of the 95% CI (0.30) leaves room for a more modest true effect.

Neither semaglutide nor tirzepatide is approved for treating or preventing heart failure or respiratory failure in RA patients. Both are approved for type 2 diabetes and chronic weight management. Any use in RA patients for cardiopulmonary protection would be off-label and should be discussed with a rheumatologist or cardiologist who can weigh individual risks and benefits.